Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity
Clinical trial NCT03746522 · COMPLETED
Trial details
- NCT number
- NCT03746522
- Sponsor
- Rhythm Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-11-23
- Primary completion
- 2020-11-16
- Enrollment
- 52
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.